'Unusual' Cancers After Pandemic; A Win in TNBC; Shortage Pauses Clinical Trial

— News, features, and commentary about cancer-related issues

Ƶ MedicalToday
Onco Break over a computer rendering of a cancer cell.

Some emerged during the pandemic, but is COVID to blame? (Washington Post)

Using routinely collected information about patients with cancer, an artificial intelligence model showed promise for predicting which patients will . (Nature Cancer)

A lower-intensity, three-drug combination, followed by stem cell transplantation (SCT), led to improved relapse-free survival in older patients with compared with intensive chemotherapy and SCT. (Cancer)

Prenatal care may offer opportunities to gain insight into a . (Weill Cornell Medicine, American Journal of Obstetrics and Gynecology)

Mutations in the estrogen signaling pathway could provide clues to the origin of and to potential new therapies. (Cancer Research)

An investigational detected significantly more cancers and precancers compared with current screening methods. (Nature Medicine)

A newly discovered protein could provide insight into what drives and clues to new treatment approaches. (Molecular Cancer)

The combination of an androgen receptor blocker and chemotherapy led to a 42% response rate in difficult-to-treat , more than twice as high as historical response rates. (Cell Reports Medicine)

AbbVie announced that its antibody-drug conjugate mirvetuximab soravtansine (Elahere) produced objective responses in 51.9% of women with heavily pretreated, folate receptor alpha-positive, .

Bristol Myers Squibb acknowledged that a forced a pause in enrollment for a phase III trial in neuroendocrine tumors. (Endpoints News)

  • author['full_name']

    Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined Ƶ in 2007.